Identifying the "Optimal" Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Revascularization

JACC: Cardiovascular Interventions

Volumn 2, Issue 12, 2009, Pages 1279-1285

  Kandzari, David E ^a   Angiolillo, Dominick J ^b   Price, Matthew J ^a   Teirstein, Paul S ^a  

^a SCRIPPS CLINIC   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

drug eluting stents; dual antiplatelet therapy; stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PLACEBO; PRASUGREL; THIENOPYRIDINE DERIVATIVE; TICAGRELOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; BLEEDING; BRAIN HEMORRHAGE; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RISK BENEFIT ANALYSIS; STENT THROMBOSIS; TREATMENT DURATION; VASCULAR DISEASE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; ENDPOINT DETERMINATION; EVIDENCE-BASED MEDICINE; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 72149124227     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.09.012     Document Type: Review

References (37)

1. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
2. Grines C.L., Bonow R.O., Casey D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with Representation from the American College of Physicians. J Am Coll Cardiol 49 (2007) 734-739
3. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
4. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
5. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
6. Win H.K., Caldera A.E., Maresh K., et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297 (2007) 2001-2009
7. Beohar N., Davidson C.J., Kip K.E., et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 297 (2007) 1992-2000
8. Smith Jr. S.C., Feldman T.E., Hirschfeld Jr. J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47 (2006) e1-e121
9. King S.B., Smith Jr. S.C., Hirschfeld Jr. J.W., et al. 2007 focused update on ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51 (2008) 172-209
10. Mehta S., Yusuf S., Peters R., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
11. Steinhubl S.R., Berger P.B., Mann J.T., et al., CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
12. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168
13. Brar S.S., Kim J., Brar S.K., et al. Long-term outcomes by clopidogrel duration and stent type on a diabetic population with de novo coronary artery lesions. J Am Coll Cardiol 51 (2008) 2220-2227
14. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
15. Park D.W., Park S.W., Park K.H., et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 98 (2006) 352-356
16. Jeremias A., Sylvia B., Bridges J., et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 109 (2004) 1930-1932
17. Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113 (2006) 2803-2809
18. Bhatt D.L., Flather M.D., Hacke W., et al., CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49 (2007) 1982-1988
19. Airoldi F., Colombo A., Morici N., et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116 (2007) 745-754
20. Roy P., Bonello L., Torguson R., et al. Temporal relation between clopidogrel cessation and stent thrombosis after drug-eluting stent implantation. Am J Cardiol 103 (2009) 801-805
21. Park D.W., Yun S.C., Lee S.W., et al. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent: data from an observational cohort study of drug-eluting versus bare-metal stents. J Am Coll Cardiol Intv 1 (2008) 494-503
22. Kimura T., Morimoto T., Nakagawa Y., et al., j-Cypher Registry Investigators. Antiplatelet therapy and stent thrombosis following sirolimus-eluting stent implantation. Circulation 119 (2009) 987-995
23. Schulz S., Schuster T., Mehilli J., et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J (2009 July 11) [E-pub ahead of print]
24. van Werkum J.W., Heestermans A.A., Zomer A.C., et al. Predictors of coronary stent thrombosis: the Dutch stent thrombosis registry. J Am Coll Cardiol 53 (2009) 1399-1409
25. Ong A.T., McFadden E.P., Regar E., de Jaegere P.P., van Domburg R.T., and Serruys P.W. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 45 (2005) 2088-2092
26. Leon M. ENDEAVOR IV: a randomized comparison of a zotarolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease, three-year results. Presented at: Transcatheter Therapeutics (TCT). San Francisco, CA (September 21, 2009)
27. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
28. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045-57.
29. Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113 (2006) 2803-2809
30. Eisenberg M.J., Richard P.R., Libersan D., and Filion K.B. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 119 (2009) 1634-1642
31. Kim J.W., Kang W.C., Kim K.S., et al. Outcome of non-cardiac surgical procedure and brief interruption of dual anti-platelet agents within 12 months following Endeavor (zotarolimus-eluting stent) stent implantation (SENS): a multicenter study. J Am Coll Cardiol 53 Suppl (2009) A16
32. Gwon H.C. Three month duration of dual antiplatelet therapy is safe after implantation of zotarolimus-eluting stents in relatively low-risk patients with coronary artery disease: findings from the DATE registry. Presented at: EuroPCR 2009. Barcelona, Spain (May 14, 2009)
33. Cutlip D.E., Windecker S., Mehran R., et al., Academic Research Consortium. Clinical endpoints in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
34. Stettler C., Wandel S., Alleman S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
35. Kaltoft A., Jensen L.O., Maeng M., et al. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare metal coronary stents. Results from the WDHR (Western Denmark Heart Registry). J Am Coll Cardiol 53 (2009) 658-664
36. Simon T., Verstuyft C., Mary-Krause M., et al., FAST MI Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360 (2009) 363-375
37. Price M.J., Berger P.B., Angiolillo D.J., et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J 157 (2009) 818-824